Navigation Links
Warning on Avastin Updated

A new label change has been proposed by the FDA for the anti-angiogenic colorectal-cancer drug Avastin (bevacizumab) to include rare cases of a reversible posterior leukoencephalopathy syndrome in its warning.//

Genentech, which markets Avastin said that the brain-capillary leak syndrome has been reported or confirmed in less than 0.1% of the estimated 60,000 cancer patients treated with Avastin.

The Adverse Reactions and Dosage and Administration sections of the Avastin label have been updated to include the warning about reversible posterior leukoencephalopathy as well as nasal septum perforation.

Genentech reported seven cases of nasal septum perforation reported in post market surveillance.

Reversible posterior leukoencephalopathy syndrome is also associated with fluid retention, hypertension and the cytotoxic effects of the immunosuppressive drugs on the vascular endothelium.

J. Leonard Lichtenfeld, M.D., deputy medical director of the American Cancer Society in Atlanta, said this not the first time that the anti-angiogenic agent has been linked with bleeding problems. He noted, for example, the perforated colon has been reported in Avastin colorectal cancer studies.

Dr. Lichtenfeld said, "This is exactly the reason that post marketing surveillance is so important for all drugs and especially for chemotherapy drugs."

According to him Avastin is "typically is given to patients with advanced disease and aggressive tumors," a patient population that is compromised by disease and thus at higher risk for side-effects.

Genetech letter’s to the clinicians said that reversible posterior leukoencephalopathy usually presents with "headache, seizure, visual disturbance, and altered mental function, and is characterized by reversibility upon control of hypertension or other instigating factors," with onset of symptoms reported to occur within 16 hours to one year of initiation of Avastin treat ment.

Magnetic resonance imaging studies are needed to confirm diagnosis.

Patients who develop symptoms of reversible posterior leukoencephalopathy should discontinue Avastin and initiate hypertension treatment, if necessary.

Genetech also says that symptoms "usually resolve or improve within days, although some patients have experienced ongoing neurologic sequelae." It is still unknown however whether Avastin can safely be reinitiated in patients who developed reversible posterior leukoencephalopathy syndrome.


NLA
'"/>




Related medicine news :

1. Early Warning System For Breast Cancer
2. Warning on radiowave exposure
3. A Seizure Late In Life Could be A Stroke Warning
4. Blood Pressure An Early Warning Sign Of Alzheimer’s Disease
5. Early Warning Signs Of Heart Disease
6. Warning Issued by FDA on consumption of the drug Tysabri used to treat Multiple Sclerosis
7. Warning issued by FDA over "Liqiang 4 Capsules"
8. Warning Signs On Powered Baby Milk
9. People Still Neglect To Use Sunscreen In Spite Of Cancer Warnings
10. Global Outbreak Of Bird Flu Warning By Chinese Scientist
11. Experts Building Bird Flu Warning System
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/22/2017)... ... March 22, 2017 , ... Cosmetic Town, an ... issue of its companion print magazine. The new magazine, scheduled for release in ... information provided by board-certified doctors from across the country. , According to the ...
(Date:3/22/2017)... (PRWEB) , ... March 23, 2017 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... BioPharma Asia Convention, currently taking place at the Suntec Singapore International Exhibition & ...
(Date:3/22/2017)... ... March 22, 2017 , ... Sam & ... assistance, financial planning, and related services to residents of the region, is embarking ... of threatened species and wild lands. , Endangered Species International is committed to ...
(Date:3/22/2017)... ... March 22, 2017 , ... Pinnacle 1 ... a robust, ongoing community enrichment program, has announced their latest charity partner. The ... provided for the critical needs of homeless families with children for thirty years. ...
(Date:3/22/2017)... ... 2017 , ... The American Society for Preventive Cardiology ... for prescribers to improve patients’ access to the revolutionary therapy for appropriate patients ... of the article entitled “PCSK9 Inhibitor Access Barriers: Issues and Recommendations: Improving ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , March 23, 2017 ... 2021, a latest research report. The global vagus nerve ... shift of surgeons focus toward minimally invasive VNS procedures. ... limited to few developed countries having high standards of ... ...
(Date:3/22/2017)... 22 de marzo de 2017   VWR ... de soluciones de productos y servicios para clientes ... ha adquirido EPL Archives, Inc., una organización de ... en todo el ciclo de vida de investigación ... muestra de archivo, almacenamiento de documentos y servicios ...
(Date:3/22/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Respiratory care devices ... over the next decade to reach approximately $38.27 billion by 2025. ... forecasts for all the given segments on global as well as ...
Breaking Medicine Technology: